Seminars in Oncology
Volume 34 , Pages S2-S6 , April 2007

Molecular Mechanisms in Barrett’s Metaplasia and Its Progression

  • Julie G. Izzo

      Affiliations

    • Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
    • Corresponding Author InformationAddress reprint requests to Julie G. Izzo, MD, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit #19, Houston, TX 77030-4009.
    • ,
  • Rajyalakshmi Luthra

      Affiliations

    • Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
    • ,
  • Tseung-Teh Wu

      Affiliations

    • Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
    • ,
  • Arlene M. Correa

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
    • ,
  • Madan Luthra

      Affiliations

    • Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
    • ,
  • Sharmila Anandasabapathy

      Affiliations

    • Department of Gastrointestinal Medicine and Nutrition, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
    • ,
  • K.S. Clifford Chao

      Affiliations

    • Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
    • ,
  • Mien-Chie Hung

      Affiliations

    • Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
    • ,
  • Bharat Aggarwal

      Affiliations

    • Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
    • ,
  • Walter N. Hittelman

      Affiliations

    • Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
    • ,
  • Jaffer A. Ajani

      Affiliations

    • Department of Gastrointestinal Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146
  3. Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg. 2003;76:S1367–S1369
  4. Buttar NS, Wang KK. Mechanisms of disease: Carcinogenesis in Barrett’s esophagus. Nat Clin Pract Gastroenterol Hepatol. 2004;1:106–112
  5. Pera M, Manterola C, Vidal O, et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:151–159
  6. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–2252
  7. Majid N. The obesity epidemic: Lessons from the war on smoking. Mo Med. 2005;102:550–554
  8. Spechler SJ. Screening for Barrett’s esophagus. Rev Gastroenterol Disord. 2002;2(suppl 2):S25–S29
  9. Cameron AJ, Zinsmeister AR, Ballard DJ, et al. Prevalence of columnar-lined (Barrett’s) esophagus (Comparison of population-based clinical and autopsy findings). Gastroenterology. 1990;99:918–922
  10. Spechler SJ. Dysplasia in Barrett’s esophagus: Limitations of current management strategies. Am J Gastroenterol. 2005;100:927–935
  11. Maley CC, Reid BJ. Natural selection in neoplastic progression of Barrett’s esophagus. Semin Cancer Biol. 2005;15:474–483
  12. Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett’s esophagus. Gastrointest Endosc Clin N Am. 2003;13:369–397
  13. Maley CC, Galipeau PC, Li X, et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res. 2004;64:7629–7633
  14. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38:468–473
  15. McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett’s esophagus. Cancer Res. 2004;64:1561–1569
  16. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–649
  17. Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20:187–190
  18. Nelsen CJ, Kuriyama R, Hirsch B, et al. Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J Biol Chem. 2005;280:768–776
  19. Wang TC, Cardiff RD, Zukerberg L, et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994;369:669–671
  20. Fu M, Wang C, Li Z, et al. Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology. 2004;145:5439–5447
  21. Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol Pathol. 1998;51:1–7
  22. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst. 2003;95:198–205
  23. Arber N, Lightdale C, Rotterdam H, et al. Increased expression of the cyclin D1 gene in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 1996;5:457–459
  24. Arber N, Gammon MD, Hibshoosh H, et al. Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol. 1999;30:1087–1092
  25. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett’s esophagus: Association with increased risk of adenocarcinoma. J Natl Cancer Inst. 2000;92:1316–1321
  26. Miller CT, Moy JR, Lin L, et al. Gene amplification in esophageal adenocarcinomas and Barrett’s with high-grade dysplasia. Clin Cancer Res. 2003;9:4819–4825
  27. Betticher DC, Thatcher N, Altermatt HJ, et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11:1005–1011
  28. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63:7056–7061
  29. Knudsen KE, Diehl JA, Haiman CA, et al. Cyclin D1: Polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25:1620–1628
  30. Casson AG, Zheng Z, Evans SC, et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer. 2005;104:730–739
  31. Geddert H, Kiel S, Zotz RB, et al. Polymorphism of p16 (INK4A) and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol. 2005;131:803–808
  32. Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: Association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006;24:259–267
  33. Aggarwal BB. Nuclear factor-kappaB: The enemy within. Cancer Cell. 2004;6:203–208
  34. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18:2195–2224
  35. Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–310
  36. Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006;24:748–754

 Supported in part by National Institutes of Health grant nos. NIH-NCI RO1 DE13157-04 (to W.N.H.), NIH-NCI EDRN CA 86390 (to M.R.S.), and the University of Texas M. D. Anderson Esophageal Multidisciplinary Research Project Grant, Riverkreek Foundation, and the Dallas, Cantu, Smith, and Park Families.

PII: S0093-7754(07)00022-X

doi: 10.1053/j.seminoncol.2007.01.005

Seminars in Oncology
Volume 34 , Pages S2-S6 , April 2007

Article Tools

* Image Usage & Resolution